Investigation of the relationship between fluconazole susceptibility, proteinase activity and ERG11-SAP2 Expression in Candida albicans strains isolated from clinical samples

Document Type : Original Articles

Authors

1 Duzce Ataturk State Hospital, Deparment of Medical Microbiology, Duzce, Turkey

2 Duzce University, Medical Faculty, Deparment of Medical Microbiology, Duzce,Turkey

3 Duzce University, Medical Faculty, Deparment of Biostatistics and Medical Informatics, Duzce, Turkey

10.22034/cmm.2024.345311.1585

Abstract

Background and Purpose: Candida albicans is currently recognised as an opportunistic pathogen that can cause many invasive infections. Resistance mechanisms and fungal virulence factors play an important role in the effectiveness of treatment. The aim of this study was to investigate the relationship between fluconazole resistance, proteinase activity and ERG11 (sterol 14-demethylase)- SAP2 (secreted aspartic protease 2) gene expression levels in C.albicans strains.
Materials and Methods:  Candida albicans strains isolated from patient samples sent to Medical Microbiology laboratory of Düzce University from various clinics were included in the study. Fluconazole susceptibilities of the isolates were determined by broth microdilution method.  The increase in fluconazole MIC values at 48 hours and proteinase activities of the isolates were analysed. ERG11 and SAP2 gene expression levels were measured by real time qPCR.
 
Results: Fluconazole resistance rate was found to be 3.14% in 127 C. albicans strains. A moderate positive correlation was found between ERG11 and SAP2 values ​​(p=0.029, r:0.655, p<0.001). There was no correlation between SAP2/ERG11 expression levels and fluconazole resistance. Proteinase positivity was detected in 81.1%, of 127 strains and no statistically significant correlation was found between proteinase activities and SAP2/ERG11 expression levels. While there was a statistically significant relationship between ERG11 expression levels and 48th hour MIC elevation, there was no statistically significant relationship between SAP2 levels and 48th hour MIC elevation.
Conclusion: In addition to the moderate positive correlation between ERG11 and SAP2 values, a significant correlation was found between ERG11 expression and fluconazole tolerance.

Keywords

Main Subjects

References

  1. Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU,et al. The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis. 2012;73(4):293-300.
  2. Walsh TH, Hayden RT, Larone DH. Yeast and Yeast Like Organisms. Medically Important Fungi: A Guide to Identification. 4th ed. Washington, DC: American Society for Microbiology Press; 2002.p.109-143.
  3. Howell SA, Hazen KC, Brandt ME. Candida, Cryptococcus, and other yeasts of medical importance. Manual of clinical microbiology. 2015:1984-2014.
  4. Lee MK, Kim HR, Kang JO, Kim MN, et al. Susceptibility and trailing growth of Candida albicans to fluconazole: results of a Korean multicentre study. Mycoses. 2007 Mar;50(2):148-9.
  5. Odoj K, Garlasco J, Pezzani MD, Magnabosco C, et al. Tracking Candidemia Trends and Antifungal Resistance Patterns across Europe: An In-Depth Analysis of Surveillance Systems and Surveillance Studies. J Fungi (Basel). 2024;10(10):685.
  6. GÜLAT S, DERELİ MD. Flukonazole Dirençli Candida albicans İzolatlarında Atım Pompa Ekspresyonlarının Araştırılması. Mikrobiyol Bul. 2014;48(2):325-34.
  7. Czajka KM, Venkataraman K, Brabant-Kirwan D, Santi SA, et al. Molecular Mechanisms Associated with Antifungal Resistance in Pathogenic Candida Cells. 2023 ;12(22):2655.
  8. Naglik JR, Challacombe SJ, Hube B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev. 2003 ;67(3):400-28.
  9. Feng W, Yang J, Ma Y, Xi Z, et al. The effects of secreted aspartyl proteinase inhibitor ritonavir on azoles‐resistant strains of Candida albicans as well as regulatory role of SAP2 and ERG11. Immun Inflamm Dis. 2021;9(3):667-80.
  10. Procop W, Church DL, Geraldine S. Hall, William M. Janda, Elmer W. Koneman, Paul C. Schreckenberger, et al. Koneman’s Color Atlas and Textbook of Diagnostic Microbiology. 7th ed. Philadelphia: 2017.
  11. Li W, Yu D, Gao S, Lin J, et al. Role of Candida albicans-secreted aspartyl proteinases (Saps) in severe early childhood caries. Int J Mol Sci. 2014;15(6):10766-79.
  12. Barros L.M, Boriollo MF.G, Alves AC.B.A, Klein M.I, et al. Genetic diversity and exoenzyme activities of Candida albicans and Candida dubliniensis isolated from the oral cavity of Brazilian periodontal patients. Arch Oral Biol.2008; 53(12):1172-8.
  13. Yenişehirli G, Bulut Y, Tunçoglu E. Phospholipase, proteinase and hemolytic activities of Candida albicans isolates obtained from clinical specimens. Mikrobiyol Bul. 2010;44(1):71-7.
  14. European committee on antimicrobial susceptibility testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 10.0. 2020.
  15. CİLO BD, TOPAÇ T, AĞCA H, SAĞLAM S, et al. Candida İzolatlarının Antifungal Duyarlılığının Belirlenmesinde Klinik Laboratuvar Standartları Enstitüsü (CLSI) ve Avrupa Antimikrobiyal Duyarlılık Testleri Komitesi (EUCAST) Sıvı Mikrodilüsyon Yöntemlerinin Karşılaştırılması. Mikrobiyol Bul. 2018;52(1):35-48.
  16. Kamai Y, Maebashi K, Kudoh M, Makimura K, et al. Characterization of mechanisms of fluconazole resistance in a Candida albicans isolate from a Japanese patient with chronic mucocutaneous candidiasis. Microbiol Immunol. 2004;48(12):937-43.
  17. Wang Q, Cai X, Li Y, Zhao J, et al. Molecular identification, antifungal susceptibility, and resistance mechanisms of pathogenic yeasts from the China antifungal resistance surveillance trial (CARST-fungi) study. Front Microbiol. 2022;13:1006375.
  18. Pfaller MA, Rhomberg PR, Messer SA, Jones RN, et al. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values. Diagn Microbiol Infect Dis. 2015;82(4):303-13.
  19. Tiryaki Y, Korkmazgil G, Eyigör M, Aydın N. The use of polymerase chain reaction in laboratory diagnosis of dermatophytosis. Mikrobiyol Bul. 2015;49(2):201-9.
  20. Erdem F, Tuncer EG, Oral B, Karakoç E, et al. Candida türlerine bağlı nozokomiyal enfeksiyonların epidemiyolojik ve mikrobiyolojik açıdan değerlendirilmesi. Mikrobiyol Bul. 2012;46(4):637-48.
  21. Franz R, Kelly SL, Lamb DC, Kelly DE, et al. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans Antimicrob Agents Chemother. 1998;42(12):3065-72.
  22. Suchodolski J, Muraszko J, Korba A, Bernat P, et al. Lipid composition and cell surface hydrophobicity of Candida albicans influence the efficacy of fluconazole–gentamicin treatment. Yeast. 2020;37(1):117-29.
  23. Feng W, Yang J, Xi Z, Qiao Z, et al. Mutations and/or overexpressions of ERG4 and ERG11 genes in clinical azoles-resistant isolates of Candida albicans. Microb Drug Resist. 2017;23(5):563-70.
  24. Park S, Perlin DS. Establishing surrogate markers for fluconazole resistance in Candida albicans. Microb Drug Resist. 2005;11(3):232-8.
  25. White TC, Holleman S, Dy F, Mirels LF, et al. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother. 2002;46(6):1704-13.
  26. Gerges MA, Fahmy YA, Hosny T, Gandor NH, et al. Biofilm Formation and Aspartyl Proteinase Activity and Their Association with Azole Resistance Among Candida albicans Causing Vulvovaginal Candidiasis, Egypt. Infect Drug Resist. 2023:5283-93.
  27. Sundstrom P. Adhesion in Candida Cell Microbiol. 2002;4(8):461-9.
  28. Mashaly GE, Zeid MS. Candida albicans genotyping and relationship of virulence factors with fluconazole tolerance in infected pediatric patients. Infect Drug Resist. 2022:2035-43.
  29. Patil S, Ugargol AR, Ns S. Comparıson of Two Methods or Detection of Secreted Aspartyl Proteinase in Urinary Isolates of Candida Natl J Med Res. 2014;4 (2):119-21.
  30. Oksuz S, Sahin I, Yildirim M, Gulcan A, et al. Phospholipase and proteinase activities in different Candida species isolated from anatomically distinct sites of healthy adults. Jpn J Infect Dis. 2007;60(5):280-3.
  31. Jafarian H, Gharaghani M, Seyedian SS, Mahmoudabadi AZ. Genotyping, antifungal susceptibility, enzymatic activity, and phenotypic variation in Candida albicans from esophageal candidiasis. J Clin Lab Anal. 2021;35(7):e23826. Gharaghani M, Shabanzadeh M, Jafarian H, Zarei Mahmoudabadi A. ABC typing and extracellular enzyme production of Candida albicans isolated from Candida vulvovaginitis. J Clin Lab Anal. 2022;36(1):e24117.
Current Medical Mycology
Volume 10, Continuous
2024
Pages 1-8

Files

History

  • Receive Date: 22 October 2024
  • Revise Date: 08 December 2024
  • Accept Date: 21 December 2024
  • Publish Date: 20 March 2025

Share

How to cite

Statistics